Premium
Front Cover: Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides (ChemMedChem 17/2018)
Author(s) -
Zamora Ana,
Gandioso Albert,
Massaguer Anna,
Buenestado Silvia,
Calvis Carme,
Hernández Jose Luis,
Mitjans Francesc,
Rodríguez Venancio,
Ruiz José,
Marchán Vicente
Publication year - 2018
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201800570
Subject(s) - conjugate , peptidomimetic , angiogenesis , chemistry , peptide , front cover , stereochemistry , combinatorial chemistry , biochemistry , cancer research , cover (algebra) , biology , mechanical engineering , mathematical analysis , mathematics , engineering
The Front Cover illustrates the ability of a nontoxic conjugate between a cyclometalated platinum(II) complex and a cyclic peptide containing the RGD sequence (‐Arg‐Gly‐Asp‐) to induce morphological changes and cell detachment of α V β 3 ‐overexpressing SK‐MEL‐28 cancer cells. This conjugate shows a similar angiogenesis pattern of activity to that of reference peptide Cilengitide at subcytotoxic concentrations in HUVEC cells. This result opens the way to target tumor vasculature through the development of a novel class of angiogenesis inhibitors based on the conjugation of compounds with high antiangiogenic activity, such as metal complexes or small organic molecules, to cyclic RGD‐containing peptides or peptidomimetic analogues. More information can be found in the Full Paper by José Ruiz, Vicente Marchán et al. on page 1755 in Issue 17, 2018 (DOI: 10.1002/cmdc.201800282).